![ChemicalBook](https://m.chemicalbook.com/Scripts/New/img/logo.png)
![Оклацитиниб структурированное изображение](/CAS/20150408/GIF/1208319-26-9.gif)
Оклацитиниб
- английское имяOclacitinib
- CAS №1208319-26-9
- CBNumberCB52667354
- ФормулаC15H23N5O2S
- мольный вес337.44
- EINECS950-980-7
- номер MDLMFCD25976611
- файл Mol1208319-26-9.mol
химическое свойство
Температура плавления | 226-228°C |
плотность | 1.316±0.06 g/cm3(Predicted) |
давление пара | 0Pa at 20-25℃ |
температура хранения | Refrigerator, Under inert atmosphere |
растворимость | DMSO (Slightly), Methanol (Slightly, Sonicated) |
пка | 11.59±0.40(Predicted) |
форма | Solid |
цвет | Off-White to Pale Beige |
InChI | InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12- |
ИнЧИКей | HJWLJNBZVZDLAQ-HAQNSBGRSA-N |
SMILES | [C@@H]1(CS(NC)(=O)=O)CC[C@@H](N(C)C2N=CN=C3NC=CC3=2)CC1 |
LogP | 1.38 at 35℃ and pH7 |
FDA UNII | 99GS5XTB51 |
рисовальное письмо(GHS)
-
рисовальное письмо(GHS)
-
сигнальный язык
предупреждение
-
вредная бумага
H302:Вредно при проглатывании.
H317:При контакте с кожей может вызывать аллергическую реакцию.
-
оператор предупредительных мер
P280:Использовать перчатки/ средства защиты глаз/ лица.
Оклацитиниб химические свойства, назначение, производство
Описание
Oclacitinib is an oral JAK inhibitor that is a drug approved by the U.S. Food and Drug Administration (FDA) for use in canine atopic dermatitis (AD). The U.S. FDA and the European Medical Association have approved a number of JAK inhibitors, including baricitinib, ruxolitinib, federatinib, tofacitinib, upadacitinib, oclacitinib, but some of these drugs are still being studied. Oclacitinib mainly shows activity against JAK1-dependent cytokines and also inhibits the function of JAK2-dependent cytokines. oclacitinib modifies the production of cytokines such as IL-4 and IL-13, which are crucial for B-cell proliferation and maturation in the pathogenesis of pemphigus foliaceus. Oclacitinib could interdict the effects of IL-6, a cytokine involved in the Toll-like receptor 4-originated signaling pathway in the bladder epithelial cells, and IL-8, which could theoretically contribute to a decreased defense against the urinary pathogens[1-4].Использование
Oclacitinib is a novel Janus kinase (JAK) inhibitor with activity against cytokines involved in allergy.Оклацитиниб поставщик
поставщик | телефон | страна | номенклатура продукции | благоприятные условия | |
---|---|---|---|---|---|
+8618058761490 | China | 49999 | 58 | ||
+86-17331933971 +86-17331933971 |
China | 2503 | 58 | ||
+86-371-86557731 +86-13613820652 |
China | 20314 | 58 | ||
0519-86626038 | CHINA | 811 | 58 | ||
+undefined-21-51877795 | China | 32760 | 60 | ||
+86-0371-86658258 +8613203830695 |
China | 29897 | 58 | ||
+86 18953170293 | China | 2931 | 58 | ||
+1-631-485-4226 | United States | 19553 | 58 | ||
+8618530059196 | China | 13069 | 58 | ||
+86 13288715578 +8613288715578 |
China | 12459 | 58 |